Home News and Events Press Release
Press Release
You can learn about a more comprehensive Argo Biopharma through the latest information.
You can learn about a more comprehensive Argo Biopharma through the latest information.
You can learn about a more comprehensive Argo Biopharma through the latest information.
Argo Biopharma to Present Promising Phase 1/2a Results of siRNA Therapeutic BW-20507 for Chronic Hepatitis B at EASL Congress 2025 (Late-Breaker)
Learn MoreArgo Biopharma to Present at the J.P. Morgan 43rd Annual Healthcare Conference
Learn MoreArgo Biopharma Announces Completion of First Participant Dosing in China Phase I Clinical Study of BW-03, a Novel RNAi Therapeutics for the Treatment of CHB
Learn MoreFirst Patient Dosed in Phase 2 Clinical Trial of Argo Biopharma BW-01, a Novel siRNA Drug for the Treatment of Severe Hypertriglyceridemia
Learn MoreArgo Biopharma has completed phase 1 clinical trials for BW-01, a siRNA candidate for cardiovascular diseases, in China and Australia.
Learn MoreShanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis.
Learn MoreArgo Biopharma closed series A+ financing of over 40 milion US dollars led by CS Capital.
Learn More
为了更好的呈现效果，移动端请竖屏浏览
